Introduction of Lung Carcinoma

​Non-IgG antibody has become an alternative to conventional IgG due to potential therapeutic effects on several human diseases, especially tumors. With years of experience in antibody development, Creative Biolabs has invested large quantities of time and energy in the development of non-IgG antibodies in order to discover more efficient therapeutic biomolecules. At present, we are dedicated to providing one-stop non-IgG antibodies development services as promising treatments for lung carcinoma.